Study of MLN8237 in Combination With Irinotecan and Temozolomide
Status:
Completed
Trial end date:
2018-07-25
Target enrollment:
Participant gender:
Summary
The goal of the first part of this clinical trial (Phase I portion) is to study the side
effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to
standard chemotherapy drugs, irinotecan and temozolomide.
The goal of the second part of this clinical trial (Phase II portion) is to learn how many
children and young adults show improvements in their neuroblastoma when treated with the
combination of MLN8237, irinotecan, and temozolomide.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium